Our inventors have discovered tetrazole and coumarin phosphonate based compounds can actively inhibit β-lactamase. Applying a patented pharmaceutical formulation to these compounds, our inventors been able to successfully increase the efficacy of a β-lactam antibiotic or reduce the amount/activity of β-lactamase . These new compounds target the most clinically problematic β-lactamase and can be combined with current treatments on the market today to increase the effectiveness of those treatments. These compounds would be useful in potentiating the action of beta-lactam antibiotics in the treatment of multi-drug resistant bacterial infections.
Tetrazole Based Inhibition Against a Variety of β-Lactamases Classes